Neuraxpharm Buccolam Acquisition Opens Up Opportunities
Strikes Deal With Takeda For The Only Buccal Midazolam Approved Across Europe
Neuraxpharm says a deal with Takeda to acquire the only buccal midazolam approved across Europe, Buccolam, not only gives the CNS specialist a strong asset but also offers the opportunity to expand its commercial footprint into the Nordics and Ireland.
You may also be interested in...
In an exclusive interview with Generics Bulletin, Neuraxpharm CEO Jörg-Thomas Dierks reveals that the company plans to expand out of Europe into other markets by acquiring companies in regions such as the US.
Neuraxpharm has expanded its footprint outside of Europe with the launch of its first product in Japan, in the form of the Buccolam value-added midazolam product gained through a deal with Takeda.
Neuraxpharm will gain a platform in Ireland after striking a deal to acquire local distribution specialist Medinutrix.